VeriSIM Life
PrivateLast Round
Grant
Apr 19, 2022
Total Funding Raised
$22.27M
Company Overview
VeriSIM Life operates in Healthcare & Life Sciences and is based in San Francisco, California. Its latest recorded funding round was a Grant round in April 2022.
VeriSIM Life is a biotechnology company that provides an AI-enabled biosimulation platform to de-risk R&D decisions and accelerate drug development.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VeriSIM Life Comparables
Compare VeriSIM Life with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Inductive Bio | 82% | |
| Bioleap | 80% | |
| Cellworks Group Inc | 78% |
For institutional investors. Book with your work email.
VeriSIM Life Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 19, 2022 | ||||
| Series A | Jan 6, 2022 | ||||
| Grant | Mar 2, 2021 | ||||
| Seed | Aug 14, 2019 | ||||
| Pre Seed | Dec 1, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
VeriSIM Life Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute on Drug Abuse | Grant |
| Twin Ventures | Seed |
| NIH RADx | Grant |
| TenOneTen Ventures | Pre Seed |
| Serra Ventures | Series A, Seed |
| Intel Capital | Series A, Seed |
| Colorcon Ventures | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 3, 2025
Won the AI in Action Award at the Reuters Global Pharma Awards.
- Sep 22, 2025
Shortlisted for the Innovation Award at the 2025 Scrip Awards.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 5, 2026
On Oct 5th '26, in the United States and Italy, VeriSIM Life announced a strategic collaboration with Italfarmaco S.p.A. to discover and develop novel HDAC-targeted therapeutic assets for neuromuscular, fibrotic, and rare diseases.
For institutional investors. Book with your work email.
VeriSIM Life Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VeriSIM Life's valuation, stock price, and market status.
Is VeriSIM Life a public or private company?
VeriSIM Life is a private company.
What is the current stock price of VeriSIM Life?
VeriSIM Life is a private company, so its shares have no public market price. Caplight tracks VeriSIM Life's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VeriSIM Life worth (valuation)?
Valuation information for VeriSIM Life is not publicly available.
Can I buy VeriSIM Life stock?
VeriSIM Life shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VeriSIM Life's last funding round?
VeriSIM Life's most recent funding round was Grant on April 19, 2022.
Who are the main investors in VeriSIM Life?
Key investors in VeriSIM Life include Serra Ventures, Morpheus Ventures, OCA Ventures.
Will VeriSIM Life IPO soon?
No public IPO plans have been announced for VeriSIM Life.
How can I track VeriSIM Life secondary market activity?
Caplight tracks bids, offers, and trades in VeriSIM Life's shares on secondary markets.